RxDoctor Payments Data

Lawrence Kempf, MD

Internal Medicine · New York, NYNPI 1215050455

Payments from drug & device makers

$24,559in general payments, 2019–2025

Across 455 payments — averaging $53.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$5K
  • AbbVie$4K
  • Boehringer Ingelheim$3K
  • Novo Nordisk$2K
  • Lilly USA, LLC$1K
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$1K
  • plus $8K from 37 others

What the payments were for

  • Food & beverage$24,514100%
  • Education$450%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$24,559 in reported general payments places this provider in the 95th percentile of 9,771 internal medicine providers in New York.

See all internal medicine providers in New York

Medicare billing

Part B allowed, 2024
$103,914
Medicare patients
105
Services billed
749

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide69$82,085
OzempicSemaglutide66$69,776
KevzaraSarilumab12$48,843
Trijardy XrEmpaglifloz/Linaglip/Metformin23$22,041
FarxigaDapagliflozin Propanediol21$20,641
JardianceEmpagliflozin14$14,117
EliquisApixaban11$11,005
Rosuvastatin Calcium152$2,394
TirosintLevothyroxine Sodium15$2,064
Levothyroxine Sodium74$1,218
Liothyronine Sodium43$1,214
Metoprolol Succinate81$1,131
Amlodipine Besylate114$933
Ezetimibe20$876
Citalopram HbrCitalopram Hydrobromide52$674

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$1,411$82,08569 claims
Novo NordiskOzempic$2,133$69,77666 claims
SanofiKevzara$312$48,84312 claims
Boehringer IngelheimTrijardy Xr, Jardiance$3,004$36,15837 claims
AstraZenecaFarxiga$5,053$20,64121 claims
PfizerEliquis$172$11,00511 claims
IBSA Pharma Inc.Tirosint$45$2,06415 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 9,771 internal medicine providers in New York.

Other internal medicine in New York

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →